list of glp 1 receptor agonists medications GLP-1/GIP and Diabetic Retinopathy: What ODs Should The GLP-1 Agonists and Obesity:

Data Availability Statement No datasets were generated or analysed during the current study.

Introduction Evidence from observational studies shows that use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with various health benefits,1 including reduced risks of incident alcohol use disorder23 and incident cannabis use disorder4 and reduced frequency of healthcare encounters for tobacco use disorder.5 However, much less is known about the association between GLP-1 receptor agonists and risks of developing other substance use disorders (SUDs), such as opioid use disorder and stimulant use disorder.6 Observational studies within populations with a pre-existing SUD have also emerged suggesting that use of GLP-1 receptor agonists is associated with reduced risks of adverse events such as opioid overdose,78 alcohol intoxication,7 and risk of hospital admission for alcohol use disorder.9 While the evidence base is growing, it does not comprehensively include all common SUDs

2013;369:145-154) found that intensive lifestyle intervention focused on weight loss did not reduce cardiovascular events in a large cohort of adults with overweight/obesity and type 2 diabetes

Beneficiaries are paying more for these drugs than they used to